4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,630,220 | -22.9% | 363,725 | +9.4% | 0.00% | 0.0% |
| Q2 2023 | $6,005,871 | +27.3% | 332,367 | +21.1% | 0.00% | 0.0% |
| Q1 2023 | $4,717,434 | -22.7% | 274,429 | -0.1% | 0.00% | 0.0% |
| Q4 2022 | $6,103,774 | +174.5% | 274,821 | -0.7% | 0.00% | 0.0% |
| Q3 2022 | $2,224,000 | +16.1% | 276,680 | +0.9% | 0.00% | – |
| Q2 2022 | $1,915,000 | -51.1% | 274,331 | +5.8% | 0.00% | -100.0% |
| Q1 2022 | $3,920,000 | -29.8% | 259,280 | +1.9% | 0.00% | 0.0% |
| Q4 2021 | $5,581,000 | +9.0% | 254,372 | +34.0% | 0.00% | 0.0% |
| Q3 2021 | $5,119,000 | +115.6% | 189,825 | +92.7% | 0.00% | – |
| Q2 2021 | $2,374,000 | -37.2% | 98,528 | +13.1% | 0.00% | -100.0% |
| Q1 2021 | $3,780,000 | – | 87,143 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |